Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esomeprazole-bismuth-amoxicillin triple therapy dose comparison for Helicobacter pylori eradication
IRCT20210518051335N1Phase 2Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of amoxicillin, esomeprazole and bismuth subsalicylate in Helicobacter pylori infection (2 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoints: Stool antigen test result, Drug acceptance and 1 more. Started Dec 2021; status: completed.
02
Drugs
amoxicillinesomeprazolebismuth subsalicylate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT20210518051335N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210518051335N1.